首都医科大学学报 ›› 2002, Vol. 23 ›› Issue (3): 229-231.

• 临床研究 • 上一篇    下一篇

干扰素治疗慢性乙型肝炎的随访研究

张文中   

  1. 北京佑安医院肝病科
  • 收稿日期:2002-02-22 修回日期:1900-01-01 出版日期:2002-07-15 发布日期:2002-07-15

Long-term Follow-up of Patients Treated with Interferon for Chronic Hepatitis B

Zhang Wenzhong   

  1. Department of Liver Disease, Beijing You'an Hospital
  • Received:2002-02-22 Revised:1900-01-01 Online:2002-07-15 Published:2002-07-15

摘要: 为探讨干扰素治疗慢性乙型肝炎的长期效果及对临床预后的影响,按同一诊断标准选择慢性乙型肝炎患者99例,分为治疗组(57例,给予α-干扰素3~5MIU治疗,疗程6个月,至少用药100支)和对照组(42例,采用一般保肝治疗,疗程相同).治疗结束后定期随访血生化指标、病毒学指标、影像学检查、病理检查等.治疗结束时和随访结束时干扰素治疗组HBeAg、HBV-DNA转阴率分别为40.4%、46.3%、42.1%、51.9%,与对照组相比干扰素组的近期、远期疗效均明显优于对照组(P<0.01).随访资料表明干扰素治疗组的临床预后亦明显好于对照组,病情稳定率高于对照组,病情波动率低于对照组.尤其是在HBV复制指标阴转的患者中,约有68.7%可保持疗效,长期随访中肝功能正常.对照组肝硬化和肝癌发生率及病死率均高于治疗组,提示干扰素有确切的抗病毒作用,同时能够减少肝硬化、肝癌等并发症的发生,提高患者的生存率.

关键词: 慢性乙型肝炎, 干扰素, 长期随访

Abstract: The objective was to evaluate the long-term effect of α-interferon(IFN)thrapy in patients with chronic hepatitis B virus infection, particularly on survival and hepatocellular carcinoma(HCC)prevention. Fifty-seven cases were treated with interferon(3~5MIU), 42 cases were treated with general therapy in contrast group. They were followed up for 2.3~5.5 years after end of therapy. Follow-up studies included clinical,biochemical and virological aspects and HCC screening every 3 to 6 months. In the treatment group, the HBeAg serum transforming negative and HBV DNA transforming negative were 40.4%、46.3%、42.1%、51.9% separately in the end of treatment and the end of follow-up, and was higher than the control group(P<0.01). The cumulative incidence of cirrhosis and HCC development was higher in the control group than in the treated group, In contrast, the cumulative survival rate was higher in the treated group. The results suggest that interferon has long-term beneficial effect in terms of HBV clearance, reduction of HCC and prolongation of survival.

Key words: chronic hepatitis B, ierferon, long-time follow-up

中图分类号: